CLINICAL TRIALS PROFILE FOR ESZOPICLONE

All Clinical Trials for eszopiclone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120250 ↗	Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder	Completed	Massachusetts General Hospital	Phase 4	2005-06-01	The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	American Academy of Sleep Medicine		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	Sunovion		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	University of Pittsburgh		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00235508 ↗	Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder	Completed	Sunovion	Phase 4	2005-06-01	To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00247624 ↗	Improving Sleep and Psychological Functioning in People With Depression and Insomnia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2005-10-01	This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
NCT00247624 ↗	Improving Sleep and Psychological Functioning in People With Depression and Insomnia	Completed	Philips Healthcare	Phase 4	2005-10-01	This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.

Clinical Trial Conditions for eszopiclone

Condition Name

Condition Name for eszopiclone
Intervention	Trials
Insomnia	27
Obstructive Sleep Apnea	11
Primary Insomnia	10
Sleep Initiation and Maintenance Disorders	5

Condition MeSH

Condition MeSH for eszopiclone
Intervention	Trials
Sleep Initiation and Maintenance Disorders	43
Sleep Apnea, Obstructive	13
Sleep Apnea Syndromes	11
Disease	7

Clinical Trial Locations for eszopiclone

Trials by Country

Trials by Country for eszopiclone
Location	Trials
United States	303
Japan	24
United Kingdom	6
India	3
Ukraine	2

Trials by US State

Trials by US State for eszopiclone
Location	Trials
Massachusetts	21
California	18
Pennsylvania	13
Ohio	12
New Jersey	11

Clinical Trial Progress for eszopiclone

Clinical Trial Phase

Clinical Trial Phase for eszopiclone
Clinical Trial Phase	Trials
Phase 4	25
Phase 3	16
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for eszopiclone
Clinical Trial Phase	Trials
Completed	56
Recruiting	6
Not yet recruiting	3

Clinical Trial Sponsors for eszopiclone

Sponsor Name

Sponsor Name for eszopiclone
Sponsor	Trials
Sunovion	35
University of California, San Diego	5
Massachusetts General Hospital	5

Sponsor Type

Sponsor Type for eszopiclone
Sponsor	Trials
Other	53
Industry	49
NIH	8